About this study: this is a multi-center study, invitation by principal investigator or subinvestigator only. This website is not a solicitation for recruitment.
Objective: The purpose of this study is to demonstrate the effectiveness and safety of ablation therapy in patients with Brugada syndrome to prevent ventricular fibrillation episodes
Hypothesis: Ablation of arrhythmogenic substrate on the epicardial surface of the right ventricular outflow track leads to normalization of the Brugada pattern and prevents spontaneous VT/VF episodes when compared to standard therapy
Enrollment: 194 patients to be randomized in a 1:1 fashion to ablation versus standard therapy
Clinical Sites: Multicenter study
Patient Population: Patients, ages 18 to 60, with symptomatic Brugada syndrome with a recent (less than 2 years) implantable cardiac defibrillator (ICD). Eligible patients will be randomized in a 1:1 fashion to catheter ablation of the arrhythmogenic substrate or close monitoring as per standard treatment.
Primary Endpoint: Freedom from VT/VF episodes in patients receiving ablation therapy.
BRAVE Study 